No Picture
News

eFFECTOR co-founder Siegfried Reich jumps to Turning Point; Antonio Gualberto starts post-Kura career at Eisai subsidiary H3

? Seasoned drug hunter Siegfried Reich has left eFFECTOR, the biotech he co-founded to discover selective translation regulators, to take up the CSO role at Turning Point Therapeutics.
“I have followed the progress Turning Point has made, and was drawn… […]

No Picture
News

Say goodbye to Tocagen, struggling brain cancer biotech to reverse merge with Forte Biosciences

Five months after a huge Phase III failure triggered mass layoffs at the company, Tocagen will sign itself out of existence.
Paul Wagner
The biotech, once focused on brain cancer, announced it has signed a reverse merger agreement with Forte Bioscience… […]

No Picture
News

A deep dive into cellular aging

Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell’s nucleus—and identified an FDA-approv… […]

No Picture
News

Axiom Real-Time Metrics is a Proud Supporter of the 16th Industry/Academia Next Generation Precision Oncology Symposium in La Jolla, CA

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services will be sponsoring and attending the 16th Academia Next Generation Precision Oncology Symposium at Moore’s Ca… […]

No Picture
News

Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain

– Updated Prescription Drug User Fee Act (PDUFA) Goal Date Is June 26, 2020 — Contract Manufacturing Site for HTX-011 Reinspected by FDA with No Observations Issued and a Recommendation for Approval Received –

SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -… […]